These findings indicate that preferential death among TAA-specific CD4+ T cells likely contributes to anti-tumor immune dysfunction in patients and suggest that the therapeutic administration of stimuli to improve the survival and poly-functionality of anti-TAA Th1 cells may yield improved therapeutic benefit(s) to patients afflicted with cancers such as melanoma. This evidence concerns the gene CD4 and neoplasm.